Brachytherapy
Volume 7, Issue 4 , Pages 280-282 , October 2008

Counterpoint: High-risk prostate cancer: The case for combination brachytherapy and external beam irradiation

  • Richard G. Stock

      Affiliations

    • Corresponding Author InformationCorresponding author. Department of Radiation Oncology, Mount Sinai School of Medicine, 1184 Fifth Avenue, Box 1236, New York, NY 10025, USA. Tel.: +1-212-241-7502; fax: +1-212-410-7194.

References 

  1. Lerner BH. The breast cancer wars. New York, NY: Oxford University Press; 2001;pp. 15–22
  2. Makarov DV, Trock BJ, Humphreys EB, et al. Updated nomogram to predict pathologic stage of prostate cancer given prostate-specific antigen level, clinical stage, and biopsy Gleason score (Partin tables) based on cases from 2000 to 2005. Urology. 2007;69:1095–1101
  3. Berglund RK, Jones JS, Ulchaker JC, et al. Radical prostatectomy as primary treatment modality for locally advanced prostate cancer: a prospective analysis. Urology. 2006;67(6):1253–1256
  4. Rodrigues-Covarrubias F, Larre S, De La Taille A, et al. The outcome of patients with pathological Gleason score ≥ 8 prostate cancer after radical prostatectomy. BJU Int. 2008;101:305–307
  5. Lau WK, Bergstralh EJ, Blute ML, et al. Radical prostatectomy for pathological Gleason 8 or greater prostate cancer: influence of concomitant pathological variables. J Urol. 2002;167:117–122
  6. Donohue JF, Bianco FJ, Kuroiwa K, et al. Poorly differentiated prostate cancer treated with radical prostatectomy: long-term outcome and incidence of pathological downgrading. J Urol. 2006;176:991–995
  7. Desireddi NV, Roehl KA, Loeb S, et al. Improved stage and grade-specific progression-free survival rates after radical prostatectomy in the PSA era. Urology. 2007;70:950–955
  8. Berglund RK, Sadetsky N, DuChane J, et al. Limited pelvic lymph node dissection at the time of radical prostatectomy does not affect 5-year failure rates for low, intermediate and high risk prostate cancer: results from CaPSURE. J Urol. 2007;177:526–529
  9. Van Den Ouden D, Hop WC, Schroder FH. Progression in and survival of patients with locally advanced prostate cancer (T3) treated with radical prostatectomy as monotherapy. J Urol. 1998;160:1392–1397
  10. Freedland SJ, Partin AW, Humphreys EB, et al. Radical prostatectomy for clinical stage T3a disease. Cancer. 2007;109:1273–1278
  11. Ward JF, Slezak JM, Blute ML, et al. Radical prostatectomy for clinically advanced (cT3) prostate cancer since the advent of prostate-specific antigen testing: 15-year outcome. BJU Int. 2005;95:751–756
  12. Lerner SE, Blute ML, Zincke H. Extended experience with radical prostatectomy for clinical stage T3 prostate cancer: outcome and contemporary morbidity. J Urol. 1995;154:1447–1452
  13. Swanson GP, Hussey MA, Tangen CM, et al. Predominant treatment failure in post-prostatectomy patients is local: analysis of patterns of treatment failure in SWOG 8794. J Clin Oncol. 2007;25:2225–2229
  14. Stock RG, Stone NN, Cesaretti JA, et al. Biologically effective dose values for prostate brachytherapy: effects on PSA failure and post-treatment biopsy results. Int J Radiat Oncol Biol Phys. 2006;64:527–533
  15. Stock RG, Ho A, Cesaretti JA, et al. Changing the patterns of failure for high-risk prostate cancer patients by optimizing local control. Int J Radiat Oncol Biol Phys. 2006;66:389–394
  16. Dattoli M, Wallner K, True L, et al. Long-term outcomes after treatment with brachytherapy and supplemental conformal radiation for prostate cancer patients having intermediate and high-risk features. Cancer. 2007;110:551–555
  17. Sylvester JE, Grimm PD, Blasko JC, et al. 15-year biochemical relapse free survival in clinical stage T1-T3 prostate cancer following combined external beam radiotherapy and brachytherapy; Seattle experience. Int J Radiat Oncol Biol Phys. 2007;67:57–64
  18. Potters L, Morgenstern C, Calugaru E, et al. 12-year outcomes following permanent prostate brachytherapy in patients with clinically localized prostate cancer. J Urol. 2005;173:1562–1566
  19. Merrick GS, Butler WM, Wallner KE, et al. Androgen deprivation therapy does not impact cause specific survival or overall survival in high risk prostate cancer managed with brachytherapy and supplemental external beam. Int J Radiat Oncol Biol Phys. 2007;68:34–40
  20. Stone NN, Potters L, Davis BJ, et al. Customized dose prescription for permanent prostate brachytherapy: insights from a multicenter analysis of dosimetry outcomes. Int J Radiat Oncol Biol Phys. 2007;69:1472–1477
  21. Morgan PB, Hanlon AL, Horowitz EM, et al. Timing of biochemical failure and distant metastatic disease for low-, intermediate-, and high-risk prostate cancer after radiotherapy. Cancer. 2007;110:68–80

PII: S1538-4721(08)00610-7

doi: 10.1016/j.brachy.2008.08.005

Brachytherapy
Volume 7, Issue 4 , Pages 280-282 , October 2008

Article Tools